证券代码：603707 证券简称：健友股份 公告编号：2025-021 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 分配比例：每 10 股派发现金红利 1.00 元（含税） 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 利润分配比例不变，相应调整利润分配总额。 本次利润分配预案不存在触及《上海证券交易所股票上市规则（2025 年 4 月修订）》（以下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规 定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经公证天业会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属 于上市公司普通股股东的净利润为 826,144,870.17 元。截至 2024 年 12 月 31 日，公司母公司期末 ...

南京健友生化制药股份有限公司 审计报告 苏公 W[2025]A696 号 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 中国 天锡 您可使用手机"扫一扫"或进入"注册会计师行业统一监管手台（bttp://acc.gav.co）"进行就可 _ 进行就"扫一扫"或进入"注册会计师行业统一监管手台（bttp://acc.gene.or） 进行就 目 录 | 序号 | 容 内 | 页码 | | --- | --- | --- | | 1 | 审计报告 | 1-5 | | 2 | 合并资产负债表 | 6-7 | | 3 | 母公司资产负债表 | 8-9 | | 4 | 合并利润表 | 10 | | 5 | 母公司利润表 | 11 | | 6 | 合并现金流量表 | 12 | | 7 | 母公司现金流量表 | 13 | | 8 | 合并所有者权益变动表 | 14-15 | | 9 | 母公司所有者权益变动表 | 16-17 | | 10 | 财务报表附注 | 18-93 | 公证天业会计师事务所(特殊普通合伙) Gongzhen ...

南京健友生化制药股份有限公司 内部控制审计报告 苏公 W[2025]E1319 号 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 中国 元锡 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行企 " 目 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | | 内部控制审计报告 | | 1-2 | | 2 | 内部控制评价报告 | | 3-7 | . 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP . 江苏. 无锡 86 (510) 68798988 86 (510) 68567788 电子信箱:mail@gztycpa.cn Wuxi. Jiangsu. China Tel: 86 (510) 68798988 Fax: 86 (510) 68567788 E-mail: mail@gztycpa.cn 内部控制审计报告 南京 ...

南京健友生化制药股份有限公司 2024 年独立董事述职报告 作为南京健友生化制药股份有限公司（以下简称为"公司"）的独立董事， 本人严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等法律、 法规和《公司章程》的规定，本着维护公司整体利益和全体股东合法权益的原则， 忠实、勤勉地履行职责，独立、客观地发表意见，审慎、理性地行使表决权，积 极推动公司健康、持续发展。现将 2024 年度（以下或称"报告期"）履行职责 的情况报告如下： 一、独立董事的基本情况： 本人崔国庆先生，1956 年出生，中国国籍，中共党员，无国外永久留居权。 毕业于南京大学，EMBA 硕士。1979 年至 1996 年，任扬州人民银行科长，1996 年至 2016 年，历任招商银行南京分行会计部总经理、行长助理、副行长。2020 年 5 月起担任公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、独立董事年度履职情况 （一）董事会和股东大会出席情况 股东大会：2024 年度，公司共召开 2 次股东大会，本人应当出席 2 次，实 际出席了 2 次，会议召开前，本人 ...

南京健友生化制药股份有限公司 2024 年独立董事述职报告 作为南京健友生化制药股份有限公司（以下简称为"公司"）的独立董事， 本人严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等法律、 法规和《公司章程》的规定，本着维护公司整体利益和全体股东合法权益的原则， 忠实、勤勉地履行职责，独立、客观地发表意见，审慎、理性地行使表决权，积 极推动公司健康、持续发展。现将 2024 年度（以下或称"报告期"）履行职责 的情况报告如下： 一、独立董事的基本情况： 本人金毅，1954 年出生，中国国籍，工商管理硕士，高级经济师，中共党 员。历任招商银行南京分行行长助理、办公室主任、无锡支行行长，招商银行南 京分行副行长、招商银行南京分行行长、招商银行巡视员。2023 年 5 月起担任 公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立 性要求，不存在影响独立性的情况。 二、独立董事年度履职情况 （一）董事会和股东大会出席情况 股东大会：2024 年度，公司共召开 2 次股东大会，本人应当出席 2 次，实 际出席了 1 次，会议召开前，本人对提交董事会的会议材料进行认真审核，与 ...

南京健友生化制药股份有限公司 ESG 管理制度 （2025 年 4 月制定） 第一条 为进一步加强南京健友生化制药股份有限公司（以下简称"公 司 "）ESG（环境、社会和公司治理）管理，推动经济社会和环境的可持续发 展，积极履行ESG 职责，根据《中华人民共和国公司法》《上市公司治理准则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上海证券交 易所上市公司自律监管指引第 14 号——可持续发展报告（试行）》等有关法 律、法规、规范性文件及《公司章程》的相关规定，结合公司实际情况，制定 本制度。 第二条 本制度所称 ESG 职责，是指公司在经营发展过程中应当履行的环 境（Environmental）、社会（Social）和公司治理（Governance）方面的责任 和义务，主要包括对自然环境和资源的保护、社会责任的承担以及公司治理的 健全和透明。 第一章 总 则 第三条 本制度所称利益相关方，是指其利益可能受到公司决策或经营活 动影响的组织或个人，包括股东（投资者）、债权人、职工、合作伙伴、客 户、供应商、社区组织和相关政府部门等。 第四条 公司应当按照本制度的要求，积极履行 ESG 职责， ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥885,219,018.08, a decrease of 11.85% compared to ¥1,004,271,789.41 in the same period last year[4] - Net profit attributable to shareholders decreased by 52.19% to ¥84,713,913.06 from ¥177,190,306.66 year-on-year[4] - Basic and diluted earnings per share were both ¥0.05, down 54.55% from ¥0.11 in the previous year[5] - Operating profit for Q1 2025 was ¥92,742,715.49, down 53.3% from ¥198,763,215.13 in Q1 2024[20] - Net profit for Q1 2025 was ¥84,711,072.67, a decline of 52.2% compared to ¥177,186,922.12 in Q1 2024[21] - The company reported a total comprehensive income of ¥84,137,863.79 for Q1 2025, significantly lower than ¥177,164,282.54 in Q1 2024, a drop of 52.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,928,306,163.95, down 6.12% from ¥9,509,950,363.94 at the end of the previous year[5] - Total assets decreased to ¥8,928,306,163.95 in Q1 2025 from ¥9,509,950,363.94 in Q1 2024, reflecting a reduction of 6.1%[18] - Total liabilities decreased to ¥2,354,943,269.67 in Q1 2025 from ¥3,021,793,728.13 in Q1 2024, a decline of 22.0%[18] - The company's equity attributable to shareholders increased by 1.31% to ¥6,576,884,929.92 from ¥6,491,670,118.25 at the end of the previous year[5] Cash Flow - The net cash flow from operating activities was ¥164,221,944.29, a decrease of 18.29% compared to ¥200,989,514.81 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was RMB 164,221,944.29, a decrease of 18.2% compared to RMB 200,989,514.81 in Q1 2024[23] - The company reported a total cash outflow from operating activities of RMB 763,063,144.43 in Q1 2025, a decrease of 3.7% from RMB 792,318,707.32 in Q1 2024[23] - The net cash flow from investment activities was RMB 360,499,633.30 in Q1 2025, recovering from a negative RMB 789,963,439.08 in Q1 2024[24] - The net cash flow from financing activities was negative RMB 612,009,101.81 in Q1 2025, contrasting with a positive RMB 481,803,012.85 in Q1 2024[24] Revenue Segments - The revenue from the heparin raw material segment decreased significantly by 51.61% year-on-year, accounting for 20.06% of total revenue, down from 25.37% in the same period last year[13] - The overall sales revenue of the formulation business grew by 18.30% year-on-year, despite some pressure on domestic formulation revenue due to product re-registration[13] - The international biopharmaceutical segment is expected to see revenue growth driven by the approval of liraglutide in April 2025, following increased investment in the sales team[13] Market Strategy - The company plans to accelerate global market expansion, focusing on regions such as mainland China, Europe, the Middle East, and Canada, to enhance the scale effect of high-quality generic drug registrations[14] - The company aims to expand its high-margin biopharmaceutical product line, establishing a third growth engine for performance[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,738[10] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[12] Research and Development - Research and development expenses for Q1 2025 were ¥69,243,203.24, a decrease of 7.1% from ¥74,903,809.77 in Q1 2024[20] Inventory and Current Assets - The company's total current assets decreased to approximately RMB 6.27 billion from RMB 7.05 billion in the previous period[16] - Inventory levels were reported at approximately RMB 3.40 billion, a decrease from RMB 3.67 billion as of December 31, 2024[16] Government Policies - The company is closely monitoring the impact of the U.S. government's tariff policies on its business, although no significant effects have been observed so far[13] Cash and Cash Equivalents - As of March 31, 2025, the company's cash and cash equivalents amounted to approximately RMB 662.89 million, down from RMB 1,024.38 million as of December 31, 2024[16] - The total cash and cash equivalents at the end of Q1 2025 were RMB 652,795,192.63, down from RMB 786,777,672.92 at the end of Q1 2024[24]

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the latest fiscal year[18]. - The company's operating revenue for 2024 was CNY 3,923,585,843.53, a slight decrease of 0.20% compared to CNY 3,931,387,279.72 in 2023[25]. - Net profit attributable to shareholders for 2024 reached CNY 826,144,870.17, a significant increase of 536.09% from a loss of CNY 189,445,790.76 in 2023[25]. - The basic earnings per share for 2024 was CNY 0.51, up 525.00% from a loss of CNY 0.12 in 2023[26]. - The weighted average return on equity increased to 13.47% in 2024, up 16.64 percentage points from -3.17% in 2023[26]. - The company achieved total revenue of 392,358.58 million RMB, a decrease of 0.20% compared to the previous year[84]. - The company's net profit attributable to shareholders increased by 536.09% to 82,614.49 million RMB[84]. - The gross profit margin for the standard heparin raw material was 30.29%, for formulations was 46.04%, and for CDMO and other products was 65.88%, with the overall gross profit margin at 43.28%[89]. Research and Development - The company has invested in new technology development, allocating 10 million yuan for R&D in the upcoming fiscal year[18]. - Research and development (R&D) investment reached RMB 53,239.37 million, representing 13.57% of total revenue, aimed at accelerating the commercialization of the R&D pipeline[36]. - The total R&D investment amounted to CNY 532,393,654.69, representing 13.57% of the operating revenue, with 38.03% of the R&D costs capitalized[99]. - The company has over 500 R&D personnel, including more than 100 with master's or doctoral degrees, enhancing its research capabilities[73]. - The company has a strong pipeline of products under regulatory review, with multiple oncology drugs currently in the documentation review phase in both China and the U.S.[125]. Market Expansion and Strategy - The company has outlined a strategic plan for market expansion, targeting a 20% increase in market share over the next two years[18]. - The company is focusing on expanding its product line, particularly in the biopharmaceutical sector, with new product launches expected in the next quarter[18]. - The company aims to enhance its market access capabilities and commercial team construction in North America, Europe, and South America, achieving significant progress[43]. - The company is expanding its product registration and sales efforts in over 20 countries, successfully entering 9 new markets during the reporting period[42]. - The company aims to provide differentiated CDMO services in the global market, enhancing its reputation and service revenue through compliance with international regulations[62]. Compliance and Governance - The company has received a standard unqualified audit report from Tianye Certified Public Accountants[8]. - The company is committed to maintaining compliance with regulatory standards, including those set by the FDA and other international bodies[18]. - The company’s board of directors and senior management have confirmed the accuracy and completeness of the financial report[6]. - The company has not faced any penalties from securities regulatory agencies in the past three years[179]. - The decision-making procedures and mechanisms regarding dividends are complete and transparent[195]. Dividend Policy - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares (including tax) to all shareholders, pending approval at the 2024 annual general meeting[9]. - The company declared a cash dividend of 16,156.35 million RMB, which represents 19.56% of the net profit attributable to ordinary shareholders in the consolidated financial statements[197]. - The company has a clear and defined dividend policy that aligns with its articles of association and shareholder resolutions[195]. - The company plans to maintain a cash dividend distribution of at least 10% of the distributable profit when conditions are met[192]. - Over the last three accounting years, the cumulative cash dividend amount (including tax) was 50,904.16 million RMB, with an average annual net profit of 57,584.41 million RMB, resulting in a cash dividend ratio of 88.40%[200]. Risk Management - The company has detailed potential risks in its future development plans, emphasizing the importance of risk management[11]. - The fluctuation in raw material prices, particularly for heparin crude products, poses a significant risk to production costs and overall financial performance[161]. - The company has developed a comprehensive response plan to enhance the likelihood of winning bids in national procurement and is actively expanding global sales channels to increase overall sales[163]. - The company has implemented a comprehensive risk management system to maintain product quality and stability, adhering to FDA audit standards[161]. Product Development and Approvals - The company received approvals for 14 generic drugs from the National Medical Products Administration of China and the FDA, expanding its injection product sales pipeline[36]. - The company completed the acquisition of Coherus BioSciences' Yusimry for USD 40 million, becoming the first Chinese company to receive full FDA approval for an adalimumab biosimilar[40]. - The company has established a complete technical system for biopharmaceuticals, with its production bases certified by the FDA, ensuring industry-leading quality control[38]. - The company is actively pursuing regulatory approvals to enhance its competitive edge in the pharmaceutical market[57][58][59]. - The company has received approvals for several products, including fluorouracil injection and voriconazole injection, with approval dates ranging from January to November 2024[126][127]. Human Resources and Management - The company has a total of 1,360 employees, with 736 in the parent company and 624 in major subsidiaries[188]. - The company has established a performance evaluation management system linked to employee responsibilities and skills, promoting various incentive measures[189]. - The company has implemented measures to significantly improve operational efficiency by shortening sales cycles, thereby reducing the impact of exchange rate fluctuations on business operations[163]. - The company is enhancing its talent development initiatives to support sustainable growth and improve operational efficiency[158]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 4.413 million yuan[177].

南京健友生化制药股份有限公司 2024 年度会计师事务所履职情况评估报告 南京健友生化制药股份有限公司（以下简称"公司"）聘请公证天业会计师 事务所（特殊普通合伙）（以下简称"公证天业"）作为公司 2024 年度财务及 内部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司 选聘会计师事务所管理办法》，公司对公证天业 2024 年审计过程中的履职情况 进行评估。经评估，公司认为公证天业资质等方面合规有效，保持了良好的独立 性，认真履职、勤勉尽责、公允表达意见，具体情况如下： 一、资质条件 公证天业创立于 1982 年，是全国首批经批准具有从事证券、期货相关业务 资格及金融业务审计资格的会计师事务所之一。2013 年 9 月 18 日，转制为特殊 普通合伙企业。执行事务合伙人/首席合伙人：张彩斌，注册地址：无锡市太湖 新城嘉业财富中心 5-1001 室。 公证天业 2024 年度经审计的收入总额 30,857.26 万元，其中审计业务收入 26,545.80 万元，证券业务收入 16,251.64 万元。2024 年度上市公司年报审计客 户家数 81 家，审计收费总额 8,151.63 万元，上 ...